Showing 1921-1930 of 5909 results for "".
- Clearside Biomedical Announces Multiple Oral Presentations to be Given at the ASRS Annual Meetinghttps://modernod.com/news/clearside-biomedical-announces-multiple-oral-presentations-to-be-given-at-the-asrs-annual-meeting/2476742/Clearside Biomedical announced that multiple oral presentations on Clearside’s pipeline and proprietary SCS Microinjector targeting the suprachoroidal space will be given at the upcoming American Society of Retinal Specialists (ASRS) annual meeting taking place July 26-30, 2019 in Chicago. <
- Bausch + Lomb Announces New Scientific Analyses Featuring Surgical And Pharmaceutical Products Will Be Presented During ASCRShttps://modernod.com/news/bausch-lomb-announces-new-scientific-analyses-featuring-surgical-and-pharmaceutical-products-will-be-presented-during-ascrs/2476509/Bausch + Lomb announced that 26 new scientific analyses, including 23 podium presentations and three posters, will feature the company’s surgical and pharmaceutical products during the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting in San Diego from
- Aerpio Pharmaceuticals Announces Uplisting to Nasdaq Capital Market and Pricing of $45 Million Public Offering of Common Stockhttps://modernod.com/news/aerpio-pharmaceuticals-announces-uplisting-to-nasdaq-capital-market-and-pricing-of-45-million-public-offering-of-common-stock/2480066/Aerpio Pharmaceuticals announced that its common stock will begin trading on the Nasdaq Capital Market under the symbol “ARPO” at the opening of trading on June 26, 2018, following its previously announced approval to list its common stock on the Nasdaq Capital Market. Aerpio also announce
- Kala Pharmaceuticals Announces Financing from Athyrium Capital Management Totaling $110 Millionhttps://modernod.com/news/kala-pharmaceuticals-announces-financing-from-athyrium-capital-management-totaling-110-million/2479817/Kala Pharmaceuticals announced the closing of Kala’s $110 million credit facility with funds managed by Athyrium Capital Management LP, a healthcare focused investment firm. “We are pleased to be partnering with Athyrium and to have their support and confidence in Inveltys for the treatmen
- OraSure Technologies’ Spit Test for COVID-19 is Coming Closerhttps://modernod.com/news/bethlehem-firms-spit-test-for-covid-19-is-coming-closer/2477975/In the shadow of the hulking Bethlehem Steel foundry, whose long-idled smokestacks stand like tombstones for the defunct industrial giant, a Pennsylvania technology company is racing to “de
- Ripple Therapeutics Announces Evaluation and Licensing Agreements with Glaukoshttps://modernod.com/news/ripple-therapeutics-announces-evaluation-and-licensing-agreements-with-glaukos/2482502/Ripple Therapeutics announced a new evaluation and licensing agreement with Glaukos this week that aims to leverage Ripple’s patented technology platform to create sustained release implants of targeted therapeutics for both glaucoma and retinal diseases. Financial terms of the de
- Retina Community Mourns the Loss of Ramin Tadayoni, MD, PhDhttps://modernod.com/news/retina-community-mourns-the-loss-of-ramin-tadayoni-md-phd/2482240/Prof. Ramin Tadayoni, MD, PhD, a giant in the global retina community, passed away on Friday. A respected leader, investigator, mentor, and educator, Prof. Tadayoni was the head of the ophthalmology department at the Fondation Adolphe de Rothschild and the Lariboisière and Saint-
- Kala Pharmaceuticals Announces FDA Acceptance of IND Application for KPI-012 for the Treatment of PCEDhttps://modernod.com/news/kala-pharmaceuticals-announces-fda-acceptance-of-ind-application-for-kpi-012-for-the-treatment-of-pced/2481312/Kala Pharmaceuticals announced that the FDA has accepted an investigational new drug (IND) application for the company’s lead product candidate, KPI-012, a human mesenchymal stem cell secretome (MSC-S), initially in development for the treatment of persistent corneal epithelial de
- Luminopia Announces FDA Approval of Digital Therapeutic to Improve Vision in Children with Lazy Eyehttps://modernod.com/news/luminopia-announces-fda-approval-of-digital-therapeutic-to-improve-vision-in-children-with-lazy-eye/2480369/Luminopia announced that the FDA has granted de novo premarket approval for Luminopia One as a prescription therapy to improve vision in children with amblyopia (lazy eye), the leading cause of vision loss in children. Luminopia One is indicated for improvement in visual acuity in child
- Topcon Receives FDA Clearance for OCT Angiography on the Maestro2 Systemhttps://modernod.com/news/topcon-receives-fda-clearance-for-octa-on-the-maestro2-system/2482439/Topcon Healthcare has received FDA 510(k) clearance for OCT angiography (OCTA) on the company’s Maestro2 robotic OCT color fundus camera system. According to Topcon, the Maestro2 offers 3×3-mm, 4.5×4.5-mm, and 6x6-mm OCTA scans, which provide the flexibility to le